Physician profile
Mark A Waldman
NPI 1811990096
$33,150.68
in general payments reported to CMS, 2019-2025
29 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $807 · 2021: $1,154 · 2022: $974 · 2023: $1,322 · 2024: $888 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,016 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,015.77 |
| Education | $214.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27,890.33 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $816.83 | 2019-2025 | |
| Janssen Biotech, INC. | $732.60 | 2019-2025 | Tremfya |
| Ucb, INC. | $416.45 | 2020-2024 | Cimzia, Bimzelx |
| Lilly USA, LLC | $407.41 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $400.46 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $330.61 | 2019-2025 | |
| Amgen INC. | $274.19 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $242.08 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $236.79 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $218.96 | 2019-2024 | Dupixent |
| Merz North America, INC. | $206.99 | 2023 | Xeomin |
| Galderma Laboratories, L.P. | $200.58 | 2020-2025 | Nemluvio |
| Incyte Corporation | $112.88 | 2022-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.80 | 2023 | Spevigo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $94.47 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $87.99 | 2021-2023 | Klisyri |
| Pfizer INC. | $86.64 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $54.33 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.86 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $38.60 | 2024-2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $30.57 | 2022-2023 | Valchlor |
| Dermira, INC. | $26.83 | 2019 | |
| Organon LLC | $20.91 | 2025 | Vtama |
| Revance Therapeutics, INC. | $16.82 | 2025 | Daxxify |
| Sebela Pharmaceuticals INC. | $15.97 | 2021 | |
| Taro Pharmaceuticals USA, INC. | $15.40 | 2019 | |
| Motiva USA, LLC | $15.33 | 2024 | |
| Dermavant Sciences, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Waldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.